Mercados españoles abiertos en 1 hr 42 mins

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
7,72-0,04 (-0,52%)
Al cierre: 04:00PM EST
8,00 +0,28 (+3,63%)
Después del cierre: 06:52PM EST

bluebird bio, Inc.

60 Binney Street
Cambridge, MA 02142
United States
339 499 9300
https://www.bluebirdbio.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo1201

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Nick LeschlyPres & Director841,95kN/A1973
Mr. William D. Baird IIIPrincipal Financial & Accounting Officer718,61kN/A1972
Mr. Andrew ObenshainCEO & DirectorN/AN/A1974
Ms. Gina R. Consylman CPAChief Financial OfficerN/AN/A1973
Mr. Kasra KasraianSr. VP of Technical Devel. & OperationsN/AN/AN/A
Ms. Jessica WhittenChief Accounting Officer & Principal Accounting OfficerN/AN/A1976
Ms. Ingrid GoldbergVP of Investor RelationsN/AN/AN/A
Ms. Helen C. FuSr. VP, Gen. Counsel & Sec.N/AN/AN/A
Ms. Elizabeth PingpankDirector of Corp. CommunicationsN/AN/AN/A
Sarah AlspachChief Communications OfficerN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2020 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. bluebird bio, Inc. has a strategic alliance with National Resilience, Inc. to research, development, and delivery of cell therapies. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de bluebird bio, Inc., a día 26 de septiembre de 2021, es 7. Las puntuaciones base son Auditoría: 5; Tablero: 7; Derechos de los accionistas: 6; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.